Generic share in the Tamsulosin market has surpassed 60%

Generic Rx amount of ₩50.7 billion in the first half of the year, ↑10% year-on-year

The original Harnal-D fell 10% from ₩36.6 billion to ₩33 billion

Hanmi with Hanmi Tams + Hanmi Tams OD, ₩13.6 billion

Harnal-D

In the Tamsulosin prostate hypertrophy treatment market worth ₩170 billion per year, Rx amount of generics increased by 10% compared to last year.

 

During the same period, the original decreased by 10%, with generic accounting for more than 60% of the total market.

 

According to UBIST, a pharmaceutical market research institute on the 2nd, the market size of Tamsulosin for prostate hypertrophy in the first half of last year is ₩83.7 billion.

 

Compared to ₩82.6 billion in the first half of last year, it increased by 1%.

 

Considering that prescriptions for prostate hypertrophy treatments are usually concentrated in the third and fourth quarters, it is expected to expand to more than ₩170 billion by the end of this year.

 

Original Rx performance is decreasing, and generic performance is gradually increasing.

 

The original Hannal-D by Astellas recorded ₩33 billion in prescription in the first half of this year.

 

Compared to ₩36.6 billion in the first half of last year, it decreased by 10%.

 

Generics increased 10% from ₩46 billion to ₩50.7 billion during the same period.

 

Its market share is 61%.

 

It surpassed 50% for the first time in the second half of 2019, and exceeded 60% in a year and a half.

 

Since the expiration of the original patent in 2015, generic has joined the market in earnest.

 

Currently, 107 companies are licensed for generics.

 

Among them, 86 companies are competing in the market.

 

Among generic companies, Hanmi posted ₩13.6 billion in prescription records in the first half alone with Hanmi Tams and Hanmi Tams OD.

 

Analysts say that the release of Hanmi Tams 0.4mg and Hanmi Toms OD, which are high-capacity products in line with market demand, was significant.

 

Genuine Science, DongKoo, Kyung Dong, and Celltrion posted more than ₩2 billion in prescriptions in the first half of the year.

 

A variable in this market is combination formulations.

 

Recently, pharmaceutical industries are developing a variety of combination formulations centered on Tamsulosin.

 

GSK's Duodart was approved in May, a compound that combines Tamsulosin with another ingredient in the treatment of prostate hypertrophy.

 

This compound is the first licensed drug in Korea.

 

Given that there is a combination of two components in the prostate hypertrophy treatment market, attention is being paid to whether a compound including two components will reorganize the market composition.

 

Development of a compound targeted at both prostate hypertrophy and irritable bladder is also in full swing.

 

Ildong and Jeil are the hypersensitivity bladder therapy ingredients for Tamsulosin.

 

Clinical treatment for a combination drugs that combines Solifenacin has been completed.

 

DongKoo and Kyung Dong are developing a combination of Tamsulosin and Mirabegron, an irritant bladder treatment ingredient.

 

Because there are many patients suffering from both diseases at the same time, it is explained that the possibility is sufficient.

 

It is also developing combined drugs that targets prostate hypertrophy and erectile dysfunction at the same time.

 

Hanmi's Gugutams (Tamsulosin+Tadalafil) was approved.

 

Chong Kun Dang is also undergoing phase 3 of the compound clinical trial, which combines the same ingredients.

 

Dongkuk and Yuyu are developing a compound that combines Dutasteride with Tadalafil.